Silexion Therapeutics Ltd. (SLXNW) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSilexion Therapeutics Ltd. (SLXNW) trades at $0.006. Silexion Therapeutics LTD is a biopharmaceutical company focused on developing RNA interference (RNAi)-based cancer drugs and delivery systems. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for SLXNW: SLXNW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
Silexion Therapeutics Ltd. (SLXNW) Healthcare & Pipeline Overview
Silexion Therapeutics LTD, founded in 2008 and based in Jerusalem, is a biotechnology firm specializing in RNAi-based cancer therapies. Their LODER delivery platform aims to treat solid tumors, with ongoing pre-clinical and clinical trials. The company operates in a competitive biotech landscape with a focus on innovative drug delivery.
What Is the Investment Thesis for SLXNW?
Silexion Therapeutics presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The company's proprietary LODER platform offers a novel approach to targeted drug delivery, potentially improving the efficacy and safety of RNAi-based cancer therapies. The successful completion of pre-clinical studies and a Phase I clinical trial for SiG12D-LODER provides initial validation of the technology. Key value drivers include the advancement of its pipeline assets through clinical development, securing strategic partnerships, and demonstrating clinical efficacy in larger patient populations. The company's small size and limited financial resources pose significant risks, as does the inherent uncertainty of drug development. With a market capitalization of $0.00B and a negative P/E ratio of -0.24, the company's valuation is speculative and dependent on future clinical and regulatory milestones. The negative beta of -0.04 suggests a low correlation with the overall market.
Based on FMP financials and quantitative analysis
SLXNW Key Highlights
Proprietary LODER delivery platform for targeted RNAi-based cancer therapies.
- SiG12D-LODER has completed pre-clinical studies and a Phase I clinical trial for pancreatic cancer.
- Pipeline includes Prostate-LODER and GBM-LODER in pre-clinical development for prostate cancer and Glioblastoma Multiforme, respectively.
- Headquartered in Jerusalem, Israel, positioning the company within the Israeli biotech ecosystem.
- Small team of 11 employees focused on research and early-stage development.
Who Are SLXNW's Competitors?
SLXNW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ACON Aclarion, Inc. | $2.38 | -2.46% | $6.86M | — |
| AKTX Akari Therapeutics, Plc | $8.72 | -1.36% | $9.98M | — |
| PIII P3 Health Partners Inc. | $6.36 | +1.44% | $20.8M | — |
| NVO Novo Nordisk A/S | $37.32 | -0.21% | $166B | 91 5-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $504.73 | -0.40% | $128B | 97 5-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $735.20 | +0.05% | $75.7B | 94 5-pillar |
| ARGX argenx SE | $919.21 | -1.79% | $57.2B | 97 5-pillar |
| ALNY Alnylam Pharmaceuticals, Inc. | $219.72 | -4.96% | $29.4B | 89 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SLXNW's Key Strengths?
Proprietary LODER delivery platform for targeted drug delivery.
- Focus on RNAi-based therapeutics, a promising area of cancer research.
- Pipeline of drug candidates targeting unmet medical needs.
- Experienced management team with expertise in drug development.
What Are SLXNW's Weaknesses?
Limited financial resources and small team size.
- Early-stage development pipeline with significant clinical and regulatory risks.
- Dependence on partnerships for further development and commercialization.
- Lack of established revenue streams.
What Are the Key Risks for SLXNW?
Financial-distress signal — its Altman Z-Score of -24.71 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays in drug development.
- Regulatory hurdles and challenges in obtaining marketing approval.
- Competition from other biotechnology and pharmaceutical companies.
- Limited financial resources and dependence on external funding.
- Patent challenges and intellectual property disputes.
What Are SLXNW's Competitive Advantages?
- Proprietary LODER delivery platform.
- Patent protection for RNAi-based drug candidates.
- Expertise in RNA interference technology.
- First-mover advantage in specific cancer targets.
What Does SLXNW Do?
Silexion Therapeutics LTD, established in 2008, is a biopharmaceutical company dedicated to the discovery and development of innovative cancer drugs and delivery systems based on RNA interference (RNAi) technology. Headquartered in Jerusalem, Israel, the company focuses on addressing the unmet needs in the treatment of malignant solid tumors. Silexion's core technology is its proprietary LODER (Local Drug EluteR) delivery platform, designed to provide sustained, local delivery of RNAi therapeutics directly to the tumor site. This targeted approach aims to maximize therapeutic efficacy while minimizing systemic side effects. The company's pipeline includes several product candidates in various stages of development. SiG12D-LODER, targeting the KRAS oncogene, has completed pre-clinical studies and an open-label Phase I clinical trial for the treatment of pancreatic cancer. Prostate-LODER is in pre-clinical development for prostate cancer, and GBM-LODER is in pre-clinical studies targeting Glioblastoma Multiforme (GBM), an aggressive primary brain tumor. Silexion's strategy involves advancing its LODER-based therapies through clinical trials and seeking partnerships for further development and commercialization. The company operates with a small team of 11 employees, reflecting its focus on research and early-stage development.
What Products and Services Does SLXNW Offer?
- Develops RNA interference (RNAi)-based cancer drugs.
- Creates delivery systems for targeted cancer therapies.
- Utilizes the proprietary LODER delivery platform.
- Focuses on treating malignant solid tumors.
- Conducts pre-clinical and clinical studies for drug candidates.
- Targets pancreatic, prostate, and brain cancers.
How Does SLXNW Make Money?
- Develops and patents RNAi-based cancer therapeutics.
- Out-licenses or partners with pharmaceutical companies for clinical development and commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
- Focuses on early-stage drug discovery and development.
What Industry Does SLXNW Operate In?
Silexion Therapeutics operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy development timelines, and significant regulatory hurdles. The market for cancer therapies is substantial and growing, driven by an aging population and increasing incidence of cancer. RNAi-based therapeutics represent a promising area of innovation, offering the potential to target previously undruggable targets. Silexion's LODER platform aims to differentiate itself by providing a localized and sustained delivery of RNAi drugs, potentially improving efficacy and reducing side effects. The company competes with other biotechnology companies developing RNAi therapeutics and drug delivery systems.
Who Are SLXNW's Key Customers?
- Potentially pharmaceutical companies seeking novel cancer therapies.
- Future patients suffering from solid tumors (indirectly).
- Research institutions interested in RNAi technology.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is a warrant, not an operating company
Insider Activity
3 transactions · 0 purchases, 0 sales, 3 other transactions · 3 identified insiders · available records within the last 180 days, newest dated Jun 4, 2026 (coverage not recorded). Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Forward Outlook
Wall Street analysts project Silexion Therapeutics Ltd. revenue of about $0 for fiscal 2026, with EPS near $-48.45.
Earnings Track Record
Silexion Therapeutics Ltd. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 2.8% below estimates on average.
Financial Health
Silexion Therapeutics Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -24.71 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Silexion Therapeutics Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Jerusalem, IL. The company is led by CEO Ilan Hadar. SLXNW has traded publicly since 2024.
SLXNW Financials
Bull Case vs Bear Case
Bull Case
- Proprietary LODER delivery platform for targeted drug delivery.
- Focus on RNAi-based therapeutics, a promising area of cancer research.
- Pipeline of drug candidates targeting unmet medical needs.
- Experienced management team with expertise in drug development.
Bear Case
- Limited financial resources and small team size.
- Early-stage development pipeline with significant clinical and regulatory risks.
- Dependence on partnerships for further development and commercialization.
- Lack of established revenue streams.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SLXNW Latest News
No recent news available for SLXNW.
SLXNW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SLXNW.
Price Targets
Wall Street price target analysis for SLXNW.
SLXNW MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SLXNW; grades run from A+ (80-100) to F (below 30).
Leadership: Ilan Hadar
CEO
Ilan Hadar serves as the CEO of Silexion Therapeutics LTD. Therefore, a comprehensive background profile cannot be generated at this time. His leadership is focused on guiding the company's strategic direction and overseeing the development of its RNAi-based cancer therapies.
Track Record: Due to the limited information available in the provided source data, it is not possible to provide a detailed track record of Ilan Hadar's achievements, strategic decisions, or company milestones under his leadership. His primary focus is currently on advancing Silexion's pipeline of drug candidates through pre-clinical and clinical development.
Common Questions About SLXNW (Healthcare)
What do analysts say about SLXNW stock?
As of 2026-03-16, there is no available analyst coverage or consensus for SLXNW stock due to its early-stage nature and limited trading activity.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on limited source data.
- Valuation metrics may not be reliable due to the company's early stage.